Alivus Life Sciences Q1 FY27 Results: Non-GPL Growth Drives Margins as GPL Business Declines
Alivus Life Sciences Limited reported its financial results for the first quarter of Fiscal Year 2027, highlighting strong growth in the non-Generic API (non-GPL) segment despite a significant de-growth in the GPL business. The company generated a strong free cash flow and expressed confidence in achieving targeted revenue growth for the full fiscal year FY27.The Q1 FY27 results demonstrated operational efficiencies across the company. Revenue from operations stood at ₹6,404 million. EBITDA for the quarter was ₹2,341 million, translating to an EBITDA margin of 36.6%. The company recorded a Profit After Tax (PAT) of ₹1,601 million, achieving a...